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Background. Leishmaniasis defines a cluster of protozoal diseases with diverse clinical manifestations. The visceral form
caused by Leishmania donovani is the most severe. So far, no vaccines exist for visceral leishmaniasis despite indications of
naturally developing immunity, and sensitive immunodiagnostics are still at early stages of development. Methodology/
Principle Findings. Establishing a proteome-serological methodology, we mapped the antigenicity of the parasites and the
specificities of the immune responses in human leishmaniasis. Using 2-dimensional Western blot analyses with sera and
parasites isolated from patients in India, we detected immune responses with widely divergent specificities for up to 330
different leishmanial antigens. 68 antigens were assigned to proteins in silver- and fluorochrome-stained gels. The antigenicity
of these proteins did not correlate with the expression levels of the proteins. Although some antigens are shared among
different parasite isolates, there are extensive differences and no immunodominant antigens, but indications of antigenic drift
in the parasites. Six antigens were identified by mass spectrometry. Conclusions/Significance. Proteomics-based dissection
of the serospecificities of leishmaniasis patients provides a comprehensive inventory of the complexity and interindividual
heterogeneity of the host-responses to and variations in the antigenicity of the Leishmania parasites. This information can be
instrumental in the development of vaccines and new immune monitoring and diagnostic devices.
Citation: Forgber M, Basu R, Roychoudhury K, Theinert S, Roy S, et al. (2006) Mapping the Antigenicity of the Parasites in Leishmania donovani
Infection by Proteome Serology. PLoS ONE 1(1): e40. doi:10.1371/journal.pone.0000040
INTRODUCTION
Leishmaniasis is endemic in 88 countries with approximately 12
million infected and 350 million people at risk (http://www.who.
int/en/). The disease is caused by parasites of the genus Leishmania,
a group of kinetoplastid protozoans, that are transmitted by
sandflies as flagellated promastigotes. With the bite of the female
vector the parasites are injected into the host to enter and multiply
in the phagolysosomes of macrophages as amastigotes [1,2].
Dependent on the Leishmania species and the immune response of
the host, there are three basic clinical manifestations of the disease:
cutaneous, mucocutaneous and visceral leishmaniasis (VL) [3,4].
VL in India, known as Kala azar, is caused by Leishmania donovani
(LD) and is the most severe form of leishmaniasis. It is
characterized by irregular bouts of fever, substantial weight loss,
hepatosplenomegaly and anemia. VL inevitably takes a fatal
course if not treated. [5]. To worsen matters, in the endemic areas
in India treatment is increasingly failing due to resistance of the
parasites to the most common anti-leishmanial drug, pentavalent
antimony [5]. New drugs such as liposomal amphotericin B and
Miltefosin are prohibitively expensive for the most affected
populations. These facts and developments stress the urgent need
for prophylactic measures and alternative therapies.
Recent studies have revealed that during endemic outbreaks in
the endemic areas the prevalence of seropositivity for the
leishmanial antigen K39 is significantly higher than the morbidity
[6] suggesting that many may have acquired a state of immunity
and, in extension, that effective vaccines against VL may be
possible. Great efforts are undertaken in search for vaccination
strategies to elicit strong, safe and effective immune responses
against Leishmania using live or killed parasites [7–11], defined
subunit vaccines [12–14], crude fractions of Leishmania parasites
[15] or DNA-vaccination [14,16–21]. The main focus in vaccine
development is the elucidation of the range and specificity of anti
Leishmania immune responses, and the identification of defined
leishmanial antigens. Knowledge of such antigens is required for
the development of vaccines. In addition, the antigens can be
instrumental in immune monitoring of infection, disease and
resistance to disease, and be used in the development of new
diagnostics. The specificities of the antibody responses will be
determined, on the one side, by the constitution, complexity and
variability of the antigenic structures of the parasites and, on the
other side, by the immunoglobulin repertoire, and the immune
and disease history of the host, and by the specific course of the
disease in the individual patients. Given this complexity of the
host-parasite-disease relationship, antigenicity and specificity
pattern rather than individual serospecificities need to be
determined for proper assessment of the immune responses in
the patients, and for correlating these responses with the clinical
outcomes of the infections and, possibly, immune protection. As
secondary, IgG-dominated antibody responses depend on T cell
help, knowledge of immunodominant serospecificities can lead to
the specificities of anti-Leishmania T cells and to the identification
of T cell epitopes, thus providing insights into the specificities of
cellular immune responses. A number of antigens are known for
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PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e40VL. Most of them were initially described for infected or
immunized animals and later tested with human sera. Only few
were identified directly for patients. A general inventory of the
range of the serospecificities in VL patients has not been attempted
yet.
With this report we present a strategy for highly resolved
mapping of serological specificities that allows to assess the range
and specificities of immune responses to complex infectious agents
such as protozoal parasites and, at the same time, to identify
specific antigens. This strategy combines Western blot seroscreen-
ing with proteome technologies involving 2-dimensional polyacryl
amid gel electrophoresis (2D-PAGE) and mass spectrometry (here,
matrix assisted laser desorption/ionisation – time of flight mass
spectrometry, MALDI-TOF MS) for the identification of the
antigens.
RESULTS
Antigenicity of Leishmania parasites in VL patients
As established by clinical diagnostics and a number of laboratory
investigations, infection of an individual with LD induces vigorous
serological and cellular immune responses [4,5]. However, the
scope of these responses in terms of the range of parasite antigens
addressed and inter-individual variations has not been unraveled
in detail. To gain detailed insights into the antigenicity of the
parasites as detected by the serological specificities of VL patients,
to assess the range of recurring and the degree of deviating
specificities in the antibody responses, and to determine whether
there is a hierarchy of antigens as to the frequencies and
magnitudes of responses induced, we separated LD protein
extracts by 1-dimensional gel electrophoresis and probed the
respective Western blots with sera of clinically diagnosed VL
patients. All the sera of VL patients were collected on the same day
at the Kala-Azar Medical Research Center of the Banaras Hindu
University located in the city of Muzaffarpur, district of
Muzaffarpur in the Indian state of Bihar. Of the 15 patients
included in this report (Table 1), most were from highly endemic
foci around Muzaffarpur. The exceptions were patients number 1,
2 and 3 who were from Motihari in the district of Purbi
Champaran, North-West of Muzaffarpur that is also highly
endemic, and patient 6 who was from the mesoendemic district
of Siwan in Western Bihar. Control sera were from 4 healthy
housemate relatives of the patients. Ten of the patients were male,
5 female. Their average age was 25 years with a range of 7 to 45
years. They had been clinically diagnosed for VL on the day blood
was drawn for serum production or up to 66 days before. The
average time between diagnosis and blood retrieval for the study
was 26 days. The time that had elapsed since the diagnosis of VL
does not indicate the time of infection, which most likely had
occurred months before, but is a rough indication of the time of
obvious symptoms with high fever as indicator of vigorous immune
responses against the infection. Seven patients were receiving
sodium antimone gluconate for therapy, 8 had not been treated
yet.
The initial 1-dimensional Western blot analysis was done with
the established LD laboratory strain AG83 as source of
Leishmania antigens. AG83 had been isolated from a VL patient
in West Bengal about 20 years earlier and did not display the
possible antigenic variations of recent endemic parasites. The blots
were developed with the same amount and dilution of serum in
each case so that the different overall intensities of the signals
reflect the different overall anti-LD serotiters, and the presence
and intensities of the individual antigen bands the differences in
the specificity patterns of the individual immune responses. The
blots obtained with the 15 patient sera shown in Figure 1 reveals
a broad range of immune specificities and extensive heterogeneity
of the serological anti-LD responses in the individual patients.
While several antigen bands occur in the blots with all sera, in no
Table 1. Patients, sera and parasites
..................................................................................................................................................
# age (yrs) sex serum code
1 parasite code
2 home district time since diagnosis (d) therapy
1 20 M P1 BHU1 Purbi Champaran
3 27 SAG
5
2 15 M P2 BHU2 Purbi Champaran 19 none
3 45 F P3 BHU3 Purbi Champaran 65 SAG
4 21 F P4 BHU4 n.a.
6 0S A G
5 32 M P5 BHU5 Muzaffarpur
4 13 none
6 30 M P6 BHU6 Siwan 3 none
7 10 F P7 BHU7 n.a. 66 SAG
8 10 F P8 BHU8 Muzaffarpur 0 none
9 30 M P9 BHU9 Muzaffarpur 11 none
10 35 M P10 n.a. Muzaffarpur 5 none
12 32 M P12 BHU12 Muzaffarpur 58 SAG
13 30 M P13 BHU13 n.a. 58 none
14 7 M P14 BHU14 Muzaffarpur 31 SAG
15 35 F P15 BHU15 Muzaffarpur 18 SAG
17 19 M P17 BHU17 Muzaffarpur 9 none
1All sera were prepared from peripheral blood drawn on the same day.
2BHU1-20 are the laboratory codes for the L. donovani isolates HMOM/IN/02/BHU1-20. All parasites were isolated from splenic aspirates taken on the same day as the
sera.
3The patients from the district Purbi Champaran were all from the city Motihari.
4The patients from the district Muzaffarpur were either from the city Muzaffarpur itself or from villages around it.
5SAG: sodium antimone gluconate.
6n.a.: not available.
doi:10.1371/journal.pone.0000040.t001
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PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e40case such shared antigens are equally dominant. In fact, the
pattern of dominant antigens reflected by the strong bands in the
blots is different for every individual VL patient analyzed. Neither
the overall intensities of the Western blot signals nor the individual
antigenicity pattern correlate with the time since diagnosis, or age
or sex of the patients. These analyses demonstrate that the
antibody responses to the parasites are highly individualized, and
that there are no uniformly dominant antigens and no recurring
hierarchies of the antigens targeted by the immune responses of
different patients.
Patterns of the anti-Leishmania serospecificities in
patients
The 1-dimensional Western blots from SDS-PAGE comprehen-
sively document the antigenicity of the parasites and the range of
the specificities of antibody responses against these parasites. The
antigen bands detected in these analysis, however, are likely to
include, depending on the specific patient serum, a varying
number of different antigens. For highly resolved analyses of the
antigenicity of LD and the specificities of the anti-parasite
antibody responses in VL patients, we ran 2-dimensional Western
blot analyses based on combinations of isoelectric focusing with
a pH range of 3 to 10 and SDS-PAGE with parasites isolated from
splenic aspirates of Patient 2 and probed the replica Western blots
with autologous serum and sera of Patients 14, 17 or 3 (Figure 2A,
B, C, D, respectively), whereby the parasites were from a patient
from Motihari as were the sera p2 and p3, whereas the sera p14
and p17 were from patients from Muzaffarpur. Since the protein
source is the same for all 4 blots shown, these analyses compare the
specificities of the antibody responses of the 4 patients. The overall
patterns of the spots are different in all 4 cases. Notwithstanding
this heterogeneity, a large number of antigens are detected by all 4
sera. The most prominent of these shared antigens are circled with
dotted lines in Figure 2A–D. The relative intensities of the signals
in the different blots differ greatly indicating that the immunoge-
nicity of the antigens differs in different patients. In addition to
recurring specificities, an even larger number of antigens is
detected by the sera of only 1 or up to 3 of the patient sera but not
by the others. The range of intensities of the divergent signals is
comparable to those of the shared ones. Some of the divergent
spots are very intense in 1 or 2 blots but completely missing from
the others. These differences are particularly noticeable in areas
with clusters of antigens where some antigens of the clusters are
detected by one serum but not by the other sera. A comparison of
the specificity patterns of the sera of patients from the 2 different
districts among each other and with the sera of patients from the
respective other district reveals no correlation, again emphasizing
the individuality of the serospecificities in responses to LD.
Differential antigenicity of LD isolates
To analyze possible variations of the antigenicity of LD parasites
we compared the 2-dimensional Western blot patterns of LD
isolates from Motihari and Muzaffarpur probed with sera from the
same or from the respective other district. This comparison is
shown with panels C–F in Figure 2. Here, BHU2 is representative
of Motihari LD isolates (Figure 2C and D) and BHU17
representative of Muzaffarpur isolates (Figure 2E and F). Both
isolates were obtained from splenic aspirates collected on the same
day. They represent the parasites of the same endemic season from
endemic foci of two adjacent districts in Bihar, India. The sera
used for the Western blots were from Patient 3 of Motihari
(Figure 2D and F) and Patient 17 of Muzaffarpur (Figure 2C and
E). Both sera produced similar antigenicity/specificity patterns
when tested with the different parasite isolates (comparing
Figure 2C with E, and D with F). These similarities of the
specificity patterns with different isolates testifies to the re-
producibility of the 2-dimensional electrophoresis. However,
despite the overall similarities of the antigen patterns detected
with the same serum, there are a number of differences which are
circled in the panels Figure 2C–F where the corresponding areas
of the antigen spots are pair-wise matched for the 2 different LD
isolates. The intensities of the antigen spots vary and some of the
weaker signals might just have dropped below detection limit in
one of the panels that are compared. However, a number of very
intense antigen spots detected in the Western blots with the BHU2
isolate are clearly missing from the Western blots with the BHU17
isolate. As it was the case for the blots with BHU2 parasites, the
antigenicity pattern of BHU17 varies with the serum (comparing
Figure 2E and F). Together, these comparisons expose differences
in antigenicity of the 2 isolates. Both isolates have clearly been
typed as L. donovani. In fact, all Leishmania parasites isolated from
the endemic regions in the Ganges plane until now were L. donovani
and were found to be of the same clade. None of the typing
protocols applied to these isolates has ever demonstrated any
species difference. Also the isolate used for the presented study had
been typed and found to be of the same species (G. Scho ¨nian et al.,
to be published shortly). The different antigenicities seen in the 2D
Western blots, thus, are antigenic variations in a closely related
cluster within the same species. The differences are particularly
Figure 1. Crude extract of Leishmania donovani AG83 cells was separated in a 12% SDS-PAGE. After transfer of the protein onto nitro cellulose each
lane was incubated separately with serum of 15 individuals with symptoms of VL (lanes 1–15) and 4 healthy donor controls (lanes 16–19).
doi:10.1371/journal.pone.0000040.g001
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e40noticeable in the case of the isolate BHU17 but also detected with
isolate BHU2. With both sera, the reactivities were found to be
weaker towards the LD antigens of the isolate obtained from the
patients themselves than against the other isolate. This observation
could be the result of selection processes by the immune system.
Identification of Leishmania antigens in visceral
leishmaniasis
The identification of antigens requires that the antigen spots of the
Western blots are assigned to protein spots in silver-stained 2-
dimensional electrophoresis gels. The high number of antigen
spots allows to identify patterns that can be compared to the
patterns obtained by protein staining and used to define the
coordinates of the matching spots. Nonetheless, high densities of
antigens and proteins in the two maps to be compared also raise
the problem that small uncertainties in aligning individual spots
might obscure proper assignment. Moreover, antigen detection by
Western blotting is more sensitive than protein detection by silver
staining. Antigens that produce intense signals in the Western blots
may, therefore, well correspond to minor spots in the silver-stained
gels. To enhance the resolution of the 2-dimensional separation
and, thereby, improve the alignments of Western blots and silver-
stained gels, we produced zoom gels with a pH range of 4.5 to 7,
the region in the 2-dimensional gels that is most densely populated
with protein spots. The proteome map obtained with the silver-
stained zoom gels for parasite BHU2 and shown with Figure 3B
displays 1067 clearly detectable protein spots, the corresponding 2-
dimensional immunoblot obtained with the autogeneous serum
some 330 antigen-spots (Figure 3A). It appears from the
comparison of proteome map and immunoblot that a high
fraction of the Leishmania proteome consists of antigens that
induced specific responses in VL patient.
Of the 330 antigens 68 could unequivocally be assigned to
protein spots in the silver-stained gels. In the remaining cases the
match was uncertain. These results were reproduced in 9
independent silver-stained gels and 3 Western blots. Of the 68
matched antigens the 6 indicated by arrows in Figure 3 were
identified from the silver-stained gel by mass spectrometry (see
below). To compare antigenicity with the expression levels of the
proteins we stained a 2-dimensional gel with the fluorescent dye
SyPro Ruby which produces spot intensities that are proportional
to the protein amount. Figure 3C shows a section of this gel with
the antigens assigned to protein spots in the silver-stained gel
Figure 2. 2D-Western blot analysis of the serospecificities of different VL patients and of the antigenicities of L. donovani isolates from different
endemic districts in Bihar, India. Whole protein extracts of L. donovani BHU2 (MHOM/IN/02/BHU2) (Panels A–D) isolated from a patient from Motihari
or BHU17 (MHOM/IN/02/BHU17) (Panels E–F) isolated from a patient from Muzaffarpur district were separated by 2-dimensional electrophoresis (pH-
range of first dimension: 3–10 on 18 cm IPG-strips; second dimension: 12.5% SDS-PAGE). The separated proteins were blotted onto nitrocellulose
membrane and probed with sera of different patients: A: patient No. 17; B: patient No. 2; C: patient No. 3; D: patient No. 14; E: patient No. 17; F:
patient No. 3. Patients 2 and 3 were from Motihari, patients 14 and 17 from Muzaffarpur. For comparison of the serospecificities shown with Panels
A–D, BHU2 proteins were probed with 4 different sera, 2 from Motihari, 2 from Muzaffarpur district. Dotted circles indicate antigens recognized by all
4 sera. Private specificities are not marked. For comparison of the antigenicities of different LD isolates shown with Panels C–F, proteins of BHU2
(Panels C and D) and BHU17 (Panels E and F) were probed with a serum from the same district and a serum from the respective other district. Circles
with full lines in panels C–F indicate antigens that are detected only in one of the two LD isolates but not in the other.
doi:10.1371/journal.pone.0000040.g002
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PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e40circled. For orientation, the 6 identified antigens are indicated with
arrows. A comparison of the Western blot in Figure 3A and the
SyPro Ruby-stained gel in Figure 3C reveals that the antigenicity
of the proteins does not correlate with their expression levels.
There are a large number of strongly expressed proteins that are
not or only very faintly detected as antigens in the Western blot
and, vice versa, a number of very intense signals in the Western
blot that correspond to very faint or even undetectable spots in the
SyPro Ruby-stained gel.
For identification, the six protein spots were excised from the
silver-stained gel and the proteins fragmented in the gels with
trypsin. The tryptic fragments were extracted and analyzed by
Figure 3. Mapping of the serospecificities of VL patients against L. donovani antigens. The proteins of total lysates of L. donovani isolate BHU2
(MHOM/IN/02/BHU2) promastigotes were separated by 2-dimensional gel electrophoresis with a pH gradient of 4.5–7 in the first dimension and
a 12.5% SDS-PAGE in the second. A: Western blot developed with autologous serum. 330 Leishmania antigens could be counted. B: The
corresponding silver-stained gel displaying 1067 protein spots. 68 of 330 antigens could be assigned to protein spots in the silver-stained gel. Six of
the protein spots, indicated by arrows and numbered 1–6, were processed for protein identification by mass spectrometry. C: Inner section of a SyPro
Ruby-stained gel with the same protein material. The proteins that match antigens detected by the Western blot analysis shown in Panel A are
circled. 54 antigenic proteins are thus marked, 14 antigenic proteins are outside the sections shown. The arrows again indicate the six identified
proteins.
doi:10.1371/journal.pone.0000040.g003
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(peptide mass fingerprints, PMF) are shown in Figure 4 for the 6
antigens. These patterns were used for MASCOT database
searches for corresponding PMF pattern generated from the
sequence database entries. The searches identified the antigens as
HSP70 (spots 1 and 2), gp63 (spot 3), the initiations factor EIF-4A
(spot 4), the elongation factor EF2 (spot 5) and grp78 (spot 6). The
percentages of matched masses and sequence coverage are listed
for each protein in Table 2. Remaining masses that could not be
assigned to the identified protein were extensively reanalyzed but
did not produce any evidence for proteins than the identified ones
which supports the identification of the antigens. Table 2 lists also
the theoretical masses and isoelectric points calculated for the
proteins from their sequences, and the corresponding experimen-
tal values deduced from the 2-dimensionen electrophoresis gel.
The identifications of the proteins were of sufficiently high
significance for HSP70, gp63 and grp78. To confirm the results
for EIF-4A and EF2, one of the matched fragments each was
subjected to post-source decay (PSD) analysis. The PSD spectra
for these 2 fragments, the assignments of the masses to the N- and
C-terminal fragment series and the interpretation of these signals
in terms of amino acid sequence are provided with Figure 5A and
B. In both cases the resulting fragment sequences,
HNLIQGLVLSPTR for the spot 4 fragment (Figure 4C and
5A) and AYLPVAESFGFTADLR for the spot 5 fragment
(Figure 4D and 5B) match exactly the sequences of the proteins
identified by PMF analysis, i.e. EIF-4A and EF2, respectively. For
the antigens in spots 1, 4, 5 and 6 the theoretical and experimental
values are in good agreement. The theoretical and experimental
masses of antigen spot 3 also agree very well with the sequence of
the identified protein gp63. The difference of about 1.4 pH units
in the pI values can be explained by the fact that gp63 is an outer-
membrane glycoprotein rich in sialic acids that confer additional
negative charges to the protein. The antigen in spot 2 was
identified, like spot 1, as HSP70. While its isoelectric point
corresponds well to the expected value, its mass is with 45 kDa
more than 20 kDa too small. For both spots, the identifications are
clear and 6 of the tryptic fragments are the same for both proteins.
An obvious explanation for the discrepancy would be that the
protein in spot 2 is a truncated version of the HSP70 found in spot
Figure 4. Identification of L. donovani antigens by mass spectrometry. The protein spots in the silver-stained gel that had been assigned to antigen
spots in the corresponding Western blot were excised, destained and incubated with trypsin. The resulting fragments were extracted from the gel
pieces and analyzed by MALDI-TOF-MS. Panels A–F show the peptide mass fingerprints (PMF) of the proteins in spots 1–6, respectively. Upon
processing via MASCOT, the antigens were identified as HSP70 (spots 1, panel A and spot 2, panel B), gp63 (spot 3, panel A), EIF-4a (spot 4, panel C),
Ef2 (spot 5, panel D) and grp78 (spot 6, panel E). The fragment masses that could be matched to theoretical trypsin digests of the identified proteins
are indicated by asterisks. Open circles indicate the autolytic fragments of trypsin that were used for internal calibration.
doi:10.1371/journal.pone.0000040.g004
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PLoS ONE | www.plosone.org 6 December 2006 | Issue 1 | e401. However, this explanation is excluded by the fact that the
tryptic fragments assigned to the protein sequences scatter along
the entire extend of the respective proteins, between sequence
position 73 and 610 for spot 1 and 51 and 610 for spot 2. The
alignment of the tryptic fragments of the spot 2 protein with the
sequence of HSP70 shows a stretch of 210 amino acids
Figure 5. Confirmation of the protein identifications for spots 4 and 5 by PSD mass spectrometry for peptide fragmentation fingerprint (PFF) analyses.
Panel A shows the PSD spectrum of a 1447 Da fragment of the protein in spot 4 and panel B that of a 1757 Da fragment from antigen spot 5. The
former was identified as the tryptic fragment HNLIQGLVLSPTR from EIF-4a corresponding to the L. major sequence of this protein and the latter as the
tryptic fragment AYLPVAESFGFTADLR of EF2 also of L. major. In both cases, the protein identification by PFM analyses were, thus, confirmed by PFF
analyses and homology to the sequences of the proteins in L. major.
doi:10.1371/journal.pone.0000040.g005
Table 2. Antigens in human visceral leishmaniasis identified by proteome serology.
..................................................................................................................................................
Spot # Identified protein reference species, gene identifier # Theoretical
Apparent values
calculated from the
2D-electrophoresis PMF results
pI Mw(kDa) pI Mw(kDa)
Matched
masses
Sequence
coverage
1 heat shock 70-related protein 1, L. major, gi|1170375 5.52 68.29 5.52 66 12/34 20%
2 heat shock 70-related protein 1 L. major, gi|1170375 5.52 68.29 5.36 45 13/41 22%
3 leishmanolysin (gp 63) L. chagasi, gi|539396 6.84 63.79 5.45 62 16/47 27%
4 eucaryotic initiation factor 4A (EIF-4A) L. major, gi|11466166 5.83 45.30 5.82 46 12/42 33%
5 elongation factor 2 (EF-2) L. major, gi|11244578 5.80 86.12 5.88 87 11/53 20%
6 glocose-regulated protein 78 (grp78) L. donovani, gi|16797868 5.19 68.87 5.11 71 10/23 16%
The proteins of L. donovani BHU2 (MHOM/IN/02/BHU2) were separated by 2DE, blotted onto a nitrocellulose membrane and probed with serum from the same patient
from whom the parasites were isolated. Antigenic proteins assigned to the proteome map were digested with trypsin and identified by mass spectrometry. The proteins
were identified by matching the experimental peptide mass fingerprints with fingerprints computed for sequence database entries or by sequencing selected tryptic
fragments by post-source decays and peptide fragmentation fingerprint analyses. The theoretical pI and mass values were calculated from the polypeptide sequences
of the identified proteins, the apparent values from the positions of the spots in the 2DE.
doi:10.1371/journal.pone.0000040.t002
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PLoS ONE | www.plosone.org 7 December 2006 | Issue 1 | e40corresponding to about 25 kDa without a matching tryptic
fragment. For spot 1 there are 2 fragments within this region.
Alternative explanations for the low mass of the protein in spot 2
could be that it is a homologue of HSP70, or product of trans- or
kinetoplastid-specific cis-RNA splicing mechanisms commonly
found in kinetoplastid protozoa such as Leishmania [22] but also
described for other species and phyla [23]. In fact, we have found
substantial heterogeneity in the 39 part of HSP70 mRNA from LD
including one clear case of trans-splicing [24]. These observations
do not prove but would fit the second explanation for the deviating
mass of the spot 2 antigen. Seroreactivity of the p2 serum towards
HSP70 had also been demonstrated with a recombinant bacterial
expression clone for the full length gene product [24], thus,
confirming the identification of this antigen.
The experiments for the assignment and identification of the
antigens was done 4 times, once with a silver-stained gel (shown in
the Figure 3), once with a Coomassie-stained gel and twice with
SyProRuby-stained gels (one example shown in Figure 3). Five of
the antigens were identified in all 4 gels, one, EF2 (spot 5) 3-times,
i.e. in the silver- and the two SyPro Ruby-stained gels, not in the
Coomassie-stained gel which is most likely due to the lower
sensitivity of Coomassie staining compared to the other two
techniques. To test the reproducibility of the spot pattern in the
protein-stained gels and Western blots, all together, 13 gels were
run with BHU2 proteins, 2 stained with SyPro Ruby, 2 with
Coomassie and 9 with silver. 4 Western blots were run. The
reproducibility of the spot pattern in the gels and blots was very
high and the 68 antigens could be assigned to the silver-stained
gels in nearly all cases.
DISCUSSION
The proteome-serological approach described here produces
comprehensive and highly resolved representations of the
antigenicity of L. donovani parasites and the specificities of anti-
Leishmania immune responses in visceral leishmaniasis patients
that is beyond the capabilities of previous attempts and
technologies. The numbers of antigens detected in 2-dimensional
immunoblots for individual patients exceed 330, a number that
corresponds to more than 30% of the number of protein spots
detectable in silver-stained electrophoresis gels for the same
parasites. Although these figures are far higher than any earlier
analyses have exposed, they still are likely to be low estimates of
the real complexity of the antibody responses against the parasites
in human leishmaniasis. A comparison of the specificity patterns of
sera from different patients reveals great differences in the antigens
targeted. No two VL patients develop antibody responses with
even closely similar profiles. Nonetheless, there is a large number
of shared specificities that can be instrumental in the development
of diagnostics or vaccines. But also these shared specificities are
represented in the different patients with different intensities and
hierarchies. There is no immunodominant antigen or set of
antigens, there is not even an antigen that dominates the immune
responses in a larger fraction of the patients. This holds true also
when the specificity patterns are compared within age and sex
groups or related to severity or the time since onset of the disease.
However, there still may be specificity patterns that are indicative
of immunity and protection against reinfection, or the likelihood of
cutaneous leishmaniasis, Post-Kala Azar Dermal Leishmaniasis
(PKDL), after initial VL [4]. As demonstrated by the data
presented here, diagnostic arrays based on seroresponses to the
sets of antigens that most often are targeted are expected to be far
more sensitive and indicative of the outcome of the disease than
simple monospecific diagnostics such as the currently widely
applied rK39 dipstick [6,25,26]. It will be up to long-term
proteome-serological follow-up studies to identify such patterns, in
particular, with individuals who are seropositive but disease-free
and patients who develop PKDL versus those who do not. The
identification of specificity patterns might also be guidance for the
search for candidate vaccine antigen. Currently, for development
of vaccines with defined antigenicity there is a focus on one or few
antigens such as LACK, LeIF, TSA, gp63 and LmSTI-1 (27,
www.who.int/vaccine_research/). Although some of these were
confirmed with the present study as relevant antigens in human
visceral leishmaniasis, it might be advisable to define sets of
antigens that correlate with protection, and to design vaccines that
induce broad and complex immune responses. As it becomes
increasingly clear that T cells are crucial for effective anti-
Leishmania immune responses, the composition of the vaccines
should be designed to address these cells as well. While there are
varying factors that could be responsible for the enormous
heterogeneity of the immune responses in VL patients, the
immunogenetics of the patients, i.e. HLA control of T cell
responses, is expected to have a major part in this. Future studies
will have to correlate the specificities of serological and cellular
immune responses with HLA genetics, and with individual courses
of the disease and development of immunity as exemplified by
seropositive but disease-free individuals.
In addition to the specificities of the anti-Leishmania immune
responses, the proteome serological analyses also show differences
in the antigenicity of the parasites, in particular, when the
seroresponses against parasites from different but neighboring
endemic areas in Bihar are compared. Most striking are losses in
antigenicity seen when the seroreactivities of individual patients
against parasites isolated from their own splenic aspirates are
compared to those against parasites isolated from patients of
a distant endemic area. Since the parasites in all cases are LD of
the same clade, these differences seem to indicate antigenicity
drifts in the parasites. They do not correlate with major differences
in the proteomes of the different parasite population as detectable
in silver-stained 2-dimensional electropherograms. Loss of antige-
nicity as indicated by these data suggests immune evasion by the
parasites. Such responses to the hosts immune responses have been
described for other protozoans such as plasmodia [28,29] and
trypanosomes [30–33], and related primarily to the persistence of
the infections in the individual host [34–36]. Long-term
persistence in a host is essential for the parasites as they have to
shelter and propagate for a sufficiently long time to have a chance
to be taken up by a sand fly vector again for re-starting their life
cycle and transmitting their progenies to new hosts. This need to
escape immune attacks for an extended period is particularly
important in the endemic areas in India where Leishmania donovani
infections are anthroponotic, i.e. without extrahuman vertebrate
host, and endemic outbreaks are spaced by extended periods of
low-prevalence [37,38].
The data presented here provide new insights into the quality
and identity of the antigens targeted by the immune systems of
leishmaniasis patients. Requena and colleagues had suggested that
anti-Leishmania antibody responses are preliminarily directed
against highly expressed conserved antigens that are typically parts
of multi-component complexes such as heat-shock proteins,
ribosomal proteins or proteins of the DNA replication and the
transcription machineries. These antigens were dubbed pananti-
gens [39,40]. While the antigens we identified fit this category of
proteins [41–45], the high numbers of antigens, many of them low
abundance proteins, would rather testify against such generaliza-
tion and suggest that, due to technical shortcomings such as
sensitivity of the analytical procedures for protein identification,
highly expressed proteins are more likely to be identified than
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antigens detected, the high antigenic coverage of the proteome of
the parasite and the great variation in the specificity profiles seen
with sera from different patients strongly suggest that many
different categories of proteins can be antigens.
As illustrated with the results presented herein, proteome
serology is a powerful and highly resolving technology that
provides an overall inventory of the antigenicity of the infectious
agents and of the specificity pattern of the immune responses
against complex pathogens. At the same time it allows to identify
defined antigens as well as antigenic patterns which may advance
the development of differential diagnostics and of vaccines.
Notwithstanding these potentials, proteome serology is also
a demanding technology with a number of difficult steps [46].
Problems may arise when protein-stained gels are compared with
Western blots to assign antigen to protein spots for subsequent
identification. With large numbers and high densities of proteins
and antigens, proper assignment can be difficult. In parts, this
problem is due to the differences in sensitivity of Western blot and
protein detections. In the work presented herein, we employed
a series of measures to define the coordinates of the antigens in the
protein-stained gels exactly (see Materials and Methods). Although
pattern recognition software may facilitate the task of assigning
antigen and protein spots, manual editing of the results appears
inevitable. In addition, the identification of the proteins by peptide
mass fingerprint or peptide fragmentation fingerprint analyses is
easily obscured by a few amino acids exchanges in the protein
sequences. The L. donovani genome has not yet been sequenced so
that the present work had to be done with information of the L.
major genome sequence database and occasional L. donovani protein
sequences. Differences in protein sequences between these two
Leishmania species can be responsible for some of the failures to
identify the antigens. In cases where the amounts of proteins in the
gels permit, the limitation of the usual peptide mass or peptide
fragmentation fingerprint analyses for protein identification in
proteomics can be overcome by de novo sequencing of tryptic
fragments [47]. Also, the rapidly progressing genome project for L.
infantum which is closely related to L. donovani will improve the
success rates in protein identification from 2-dimensional electro-
phoreses. In any case, sensitivity remains a problem. Since
prominent antigens are not necessarily highly expressed proteins,
their identification often fails due to lack of sufficient amounts of
material for mass-spectrometric identification. Despite these
difficulties, proteome serology appears to be superior to other
approaches to antigen discovery and will yield substantial new
information that will be instrumental in the development of new
diagnostics and vaccines.
MATERIALS AND METHODS
Parasites and sera
LD used are MHOM/IN/02/BHU2 (BHU2), MHOM/IN/02/
BHU17 (BHU17) and AG83. BHU2 and BHU17 are recent
isolates from spleen aspirates of VL patients from highly endemic
foci in Bihar, India [24]. The time courses of growth of the isolates
and lines used in the study were established and all parasites
harvested for analyses from the same time point of late-log growth
phase of early-passage cultures. The parasites were cultured as
promastigotes in medium M199 (Gibco BRL, Heidelberg) with
20% FCS (Biochrom AG, Berlin), 20 mM HEPES, 4 mM
sodiumbicarbonate and 20 U/ml penicillin/streptomycin at
22uC. The sera used for Western blot analysis were from 15
Indian VL patients (P1–10, 12–15 and 17) and, as controls, 4
healthy housemate relatives (H1–H4) of patients. The numbering
of the patient sera matches the numbering of the parasite isolates,
thus, sera P2 and P17 were from the same patients as the parasite
isolates BHU2 and BHU17. The study had been reviewed and
approved by the institutional ethics committees of the Kala Azar
Medical Research Center, Banaras Hindu University, Varanasi,
the Indian Institute of Chemical Biology (IICB), Calcutta and the
Charite ´ – Universita ¨tsmedizin Berlin as well as by the Indian
national ethics committee at the Indian Council of Medical
Research (ICMR) and the Indian Health Ministry’s Screening
Committee.
Protein sample preparation
The parasites were harvested by centrifugation at 2,050 6 g for
30 minutes at 20uC, washed thrice with PBS and solubilized in
lysis buffer (7 M urea, 2 M thiourea, 2.5% Triton X-100, 2% b-
mercaptoethanol, 0.8% Pharmalyte pH 3.5–10 (LKB, Freiburg,
Germany), 200 mM PefablockH (Merck, Darmstadt), 1 mM
pepstatin (SIGMA, Munich, Germany) and 10 mM leupeptin
(SIGMA, Munich, Germany) as adapted from Go ¨rg and Chan
[48,49] by vortexing and sonicating for 10 minutes in an ice
cooled waterbath. The cell extracts were then incubated for one
hour at room temperature (RT) with 4,000 U/ml benzonase
(Merck, Darmstadt, Germany) to degrade nucleic acids and then
centrifuged at 350,000 6 g for 15 minutes at 15uC. The
supernatants were collected, incubated one more time with
Benzonase for 10 minutes at RT and cleared by ultracentrifuga-
tion as before.
Two-dimensional polyacrylamid gel electrophoresis
Isoelectric focussing (IEF) was done in immobilized pH-gradient
gel strips (IPG strips 180 mm63 mm; Pharmacia, Freiburg) with
pH ranges of 4 to 7 or 3 to 10 [48,49]. Approximately 100 mg
protein, extract of 1610
8 cells, in 350 ml solubilization buffer were
applied per IPG strip. The samples were loaded overnight at RT
by in-gel re-swelling under silicon oil in a nitrogen and water
saturated atmosphere to prevent oxidation of the protein and
drying of the gel strips. The loaded IPG strips were rinsed,
mounted on a cooled ceramic plate and connected with the
electrodes via water-wetted paper bridges to the electrode buffers.
The IEF was run at 20uC under silicon oil in a nitrogen- and
water-saturated atmosphere. The electric parameter were
0.15 mA per IPG strip and voltage settings stepwise increased
18 h 50 V, 1 h 150 V, 2 h 300 V, 1 h 600 V, 24 h 3,500 V and
3 h 5,000 V for a total of 101,250 Vh for pH 4–7 IPG strips and
18 h 50 V, 1 h 150 V, 2 h 300 V, 1 h 600 V, 6.5 h 3,500 V and
3 h 5,000 V for a total of 40,000 Vh for pH 3–10 IPG strips.
After the run, the IPG-strips were stored at 220uC. For the
second dimension, the IPG strips were thawed, rinsed with
ultrapure water and equilibrated to SDS-PAGE conditions for
15 minutes in equilibration buffer (6 M urea, 30% glycerol, 2%
sodium dodecylsulfate (SDS), Tris pH 6.8 and bromophenol blue,
1% dithiothreitol (DTT)) followed by 15 minutes in the same
buffer but with 4% iodoacetamide instead of DTT. The
equilibrated IPG-strips were rinsed with de-ionized water and
placed gel-side to gel-side onto the 4.8% acryl amide, 0.13%
bisacryl amide stacking gel of a horizontal SDS polyacrylamide gel
with a 12.3% acryl amide, 0.34% bisacryl amide separation gel.
The settings for the runs were 1,000 V, 40 W and 20 mA for 2–
3 h for the pre-run to transfer the protein from the IPG strip into
the SDS polyacrylamid gel, followed by 1,000 V, 40 W and
40 mA for the separation until the running front reached the
anodic end of the gel.
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The gels were stained with the highly sensitive silver staining
approach according to Blum and colleagues [50]. Briefly, SDS-
PAGE gels were fixed in a solution of 40% Methanol and 10%
acetic acid for one hour or overnight. Then, the gels were washed
thrice for 20 minutes in ultrapure water, sensitized for one minute
in 0.02% sodium thiosulfate, washed three times for 20 seconds in
water and incubated for 20 minutes in silver-staining solution
(0.2% silver nitrate, 0.0074% formaldehyde). After washing thrice
for 20 seconds in water, the gels were incubated in developing
solution (6% sodium carbonate, 0.00015% formaldehyde,
0.0004% sodium thiosulfate) until protein spots are visible. The
reactions were stopped with 0.025% EDTA in water. SyPro Ruby
(Invitrogen, Heidelberg, Germany) staining was done according to
the manufacturer’s instructions.
Western blot
The proteins from unstained SDS-PAGE were transferred onto
nitrocellulose membranes (Schleicher & Schu ¨ll, Dassel, Germany)
by semi-dry blotting for 2 hours at 400 mA. Free binding sites on
the membranes were blocked with 5% low fat milk powder in Tris-
buffered saline (TBS) for one hour at room temperature or at 4uC
overnight. After blocking, the membranes were incubated with
patient sera at a 2,000-fold dilution for one hour at room
temperature, washed thrice for 10 minutes with TBS and
incubated for 30 min with alkaline phosphatase-labelled anti
human IgG (Anti-Human Ig-AP, Fab fragment; Boehringer
Mannheim) at a 5,000-fold dilution. After washing three times
for 10 minutes with TBS, the membranes were equilibrated to
developing buffer (100 mM NaCl, 100 mM Tris-HCl, pH 9.5)
and developed in the dark with 100 ml BCIP and 100 ml NBT in
100 ml developing buffer until antigen spots are visible. The
reactions were stopped by replacing the developing solution with
water. For 1-dimensional Western blots, the parasite proteins were
separated by SDS-PAGE, 12% acryl amide, 0.8% bis-acryl amide,
and blotted 1 h with 60 mA and processed as above.
Matching antigens and protein spots
To match antigen spots in Western blots with the corresponding
protein spot in the silver-stained gel, the coordinates of the blots
and the gel were defined, first, with artificial spots at the corner
points, Ponceau S staining of the blot filter and aligning the spot
pattern with the spot pattern of the silver-stained gel and partial
blotting of a master gel and definition of marker spot sets, second,
definition of spot pattern in the local environments of the antigen
spots to match blots and gels in these local regions accurately,
third, comparing the sizes and shapes of the antigen and protein
spots and considering only those that are alike in these two
parameter.
In-gel digestion of protein
The protein spots were excised manually with a self-made spot
picker and de-stained as described by Gharadaghi and colleagues
[51] with 50 ml of Farmer’s reducing solution (15 mM potassium
ferricyanide and 50 mM sodium thiosulfate, both dissolved in
water) and then washed three times for 5–10 minutes with 150 ml
water. Afterwards the gel spots were soaked in acetonitrile and
dried under vacuum. The gel pieces were re-swollen in 7.5 mlo f
5 mM ammonium bicarbonate with 75 ng of modified porcine
trypsin (sequencing grade, modified; Promega; Madison, USA) to
fragment the protein. After 10 minutes, 7.5 mlo f5 m M
ammonium bicarbonate were added and the solution with the
gel pieces incubated for at least 4 hours in a 37uC water bath. For
MS analysis, 1.5 ml of the aqueous supernatants were mixed with
1 ml of 2,5-dihydroxybenzoic acid (DHB) (SIGMA, Munich,
Germany) (5 mg/ml water) directly on MALDI targets (MTP
AnchorChip 600/384, Bruker Daltonik, Bremen) and air-dried.
Mass spectrometry
The mass spectrometry (MS) was done with a Reflex IV MALDI-
TOF mass spectrometer (MS; Bruker Daltonik, Bremen) in
reflection mode at an acceleration voltage of 20 kV. The MS
was calibrated either with angiotensin II (1046.5 Da), angiotensin
I (1296.6 Da), bombesin (1619.8 Da), substance P (1347.7 Da),
ACTH 1–17 (2093.0 Da) and ACTH 18–39 (2465.1 Da) as
external standards and with the autolytic 842.50 Da and
2211.10 Da trypsin fragments as internal standards. Monoisotopic
peptide masses were measured. The spectra were processed by the
‘‘Xmass’’ software (Bruker Daltonik, Bremen) and the peaks
annotated manually. Post-source decay (PSD) analyses were done
in 12 sections for the entire mass range and data accumulated with
up to 300 shots per section.
Database analyses
The peak lists of the mass spectra were used for peptide mass
fingerprint analyses with the Mascot software (Matrix Science;
http:www.matrixscience.com/search_form_select.html) and pro-
found (prowl; http://prowl.rockefeller.edu/profound_bin/Web-
ProFound.exe) together with the NCBI sequence database. Most
proteins were identified using the following parameter: database:
eukaryota (eucaryotes); enzyme: trypsin; variable modifications:
oxidation (M), propionamide (C); mass values: monoisotopic;
protein mass: unrestricted; peptide mass tolerance: 6 100–
200 ppm; peptide charge state: 1+; maximum missed cleavages:
1. The analyses of the PSD datasets were done either by peptide
mass fingerprint or peptide fragmentation fingerprint analysis with
Mascot.
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